Broker tips: Dr Martens, M&G, Aviva
13th Nov 2023 11:32
(Sharecast News) - Dr Martens slumped on Monday after Barclays downgraded shares of the iconic bootmaker to 'equalweight' from 'overweight' and cut the price target to 140p from 174p.
Read moreDr Martens slumps on Barclays downgrade
13th Nov 2023 10:55
(Sharecast News) - Dr Martens slumped on Monday after Barclays downgraded shares of the iconic bootmaker to 'equalweight' from 'overweight' and cut the price target to 140p from 174p.
Read moreDr Martens' US turnaround could see shares recover, says Edison
22nd Sep 2023 12:27
(Sharecast News) - Equity research firm Edison reckons that Dr Martens' recent share-price underperformance could reverse if the iconic footwear retailer has a successful turnaround of operational issues in North America.
Read moreSparta Capital builds stake in Dr.Martens
31st Jul 2023 08:00
(Sharecast News) - Activist investor Sparta Capital has built up a stake in Dr Martens.
Read moreDirector dealings: Dr Martens chief buys the dip, HICL board member invests
17th Jul 2023 16:34
(Sharecast News) - Dr Martens was among those companies on the list of director buys on Monday, after its chief executive officer added more than 300,000 shares to his holding.
Read moreBank of America Merrill Lynch ups Dr Martens to 'buy'
14th Jul 2023 14:58
(Sharecast News) - Dr Martens surged on Friday after Bank of America Merrill Lynch lifted the stock to 'buy', arguing that the iconic bootmaker has an "attractive value proposition".
Read moreDr Martens sees progress on rectifying US issues, trading in line
13th Jul 2023 07:01
(Sharecast News) - UK bootmaker Dr Martens said progress had been made rectifying the US warehousing fiasco that led to a series of profit warnings, and trading since the start of the current financial year had been in line with expectations.
Read moreRBC Capital Markets cuts Dr Martens price target as it lowers estimates
12th Jun 2023 09:03
(Sharecast News) - RBC Capital Markets slashed its price target on Dr Martens on Monday to 150p from 180p, keeping the rating at 'sector perform', as it lowered estimates after the bootmaker's results.
Read moreBroker tips: Housebuilders, Dr Martens, REITS
12th Jun 2023 07:48
(Sharecast News) - UBS has upgraded Crest Nicholson, Persimmon and Vistry Group in its latest review of UK housebuilders.
Read moreBroker tips: Dowlais, Rio Tinto, Dr Martens
5th Jun 2023 07:36
(Sharecast News) - Jefferies initiated coverage of Dowlais - which was recently spun off from Melrose Industries - on Monday with a 'buy' rating and 155p price target, offering upside of around 21%.
Read moreDr Martens sees lower core margins in 2024 after US blunder
1st Jun 2023 07:04
(Sharecast News) - Shares in Dr Martens tanked on Thursday as the UK bootmaker posted a slump in annual earnings and said it expected lower core margins in 2024 as it incurred extra costs after blunders at its Los Angeles distribution centre.
Read moreBroker tips: Dr Martens, Hollywood Bowl, Babcock
30th May 2023 13:33
(Sharecast News) - RBC Capital Markets downgraded shares of iconic bootmaker Dr Martens on Tuesday to 'sector perform' from 'outperform' and slashed the price target to 180p from 230p as it said FY24 guidance may prove too optimistic.
Read moreRBC Capital downgrades Dr Martens, slashes price target
30th May 2023 09:27
(Sharecast News) - RBC Capital Markets downgraded shares of iconic bootmaker Dr Martens on Tuesday to 'sector perform' from 'outperform' and slashed the price target to 180p from 230p as it said FY24 guidance may prove too optimistic.
Read moreDr Martens lowers profits guidance again; CFO to retire
14th Apr 2023 07:03
(Sharecast News) - Shares in Dr Martens surged on Friday, despite the UK bootwear maker lowering profit guidance for the third time in five months as operational mistakes at its Los Angeles distribution centre cost more than anticipated.
Read moreNumis starts Dr Martens at 'add'
24th Feb 2023 09:49
(Sharecast News) - Numis initiated coverage of Dr Martens on Friday with an 'add' rating and 180p target price, which it said offers 17% total shareholder return.
Read more